Peptides and psychiatry, Part 3: substance P and serendipity: novel psychotropics are a possibility.
Stahl
S M
SM
Clinical Neuroscience Research Center in San Diego and the Department of Psychiatry at the University of California San Diego, USA.
D000928:Antidepressive Agents / Q000494:pharmacology; D015195:Drug Design; D005544:Forecasting; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D011600:Psychopharmacology / Q000639:trends; D011619:Psychotropic Drugs / Q000494:pharmacology*; D018040:Receptors, Neurokinin-1 / Q000187:drug effects; D018041:Receptors, Neurokinin-2 / Q000187:drug effects; D018042:Receptors, Neurokinin-3 / Q000187:drug effects; D013373:Substance P / Q000037:antagonists & inhibitors* / Q000502:physiology*; D015320:Tachykinins / Q000037:antagonists & inhibitors / Q000502:physiology
D000928:Antidepressive Agents; D011619:Psychotropic Drugs; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D015320:Tachykinins; D013373:Substance P